RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation

Neoplasia (United States)

Volumn 14, Issue 6, 2012, Pages 476-486

  Cho, Hyun Soo ^a   Hayami, Shinya ^a,b   Toyokawa, Gouji ^a   Maejima, Kazuhiro ^a   Yamane, Yuka ^a   Suzuki, Takehiro ^c   Dohmae, Naoshi ^c   Kogure, Masaharu ^a   Kang, Daechun ^a   Neal, David E ^d   Ponder, Bruce A J ^d   Yamaue, Hiroki ^b   Nakamura, Yusuke ^a,d   Hamamoto, Ryuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c RIKEN   (Japan)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LYSINE; METHYLTRANSFERASE; ONCOPROTEIN; PHOSPHOTRANSFERASE; PROTEIN SMYD2; RETINOBLASTOMA PROTEIN; SERINE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; ANIMAL CELL; ARTICLE; BLADDER CANCER; CANCER GROWTH; CELL CYCLE PROGRESSION; CLONOGENESIS; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TANDEM MASS SPECTROMETRY; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

EID: 84865642314     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12656     Document Type: Article

References (44)

1. Burkhart DL and Sage J (2008). Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8, 671-682.
2. Knudsen ES and Knudsen KE (2008). Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 8, 714-724.
3. Weinberg RA (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
4. Sherr CJ (1996). Cancer cell cycles. Science 274, 1672-1677.
5. Sherr CJ and McCormick F (2002). The RB and p53 pathways in cancer. Cancer Cell 2, 103-112.
6. Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, and La Thangue NB (2001). Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 3, 667-674.
7. Nguyen DX, Baglia LA, Huang SM, Baker CM, and McCance DJ (2004). Acetylation regulates the differentiation-specific functions of the retinoblastoma protein. EMBO J 23, 1609-1618.
8. Pickard A, Wong PP, and McCance DJ (2010). Acetylation of Rb by PCAF is required for nuclear localization and keratinocyte differentiation. J Cell Sci 123, 3718-3726.
9. Brown MA, Sims RJ III, Gottlieb PD, and Tucker PW (2006). Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol Cancer 5, 26.
10. Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, and Berger SL (2006). Repression of p53 activity by Smyd2-mediated methylation. Nature 444, 629-632.
11. Kawamura S, Yoshigai E, Kuhara S, and Tashiro K (2008). Smyd1 and Smyd2 are expressed in muscle tissue in Xenopus laevis. Cytotechnology 57, 161-168.
12. Diehl F, Brown MA, van Amerongen MJ, Novoyatleva T, Wietelmann A, Harriss J, Ferrazzi F, Bottger T, Harvey RP, Tucker PW, et al. (2010). Cardiac deletion of Smyd2 is dispensable for mouse heart development. PLoS One 5, e9748.
13. Gottlieb PD, Pierce SA, Sims RJ, Yamagishi H, Weihe EK, Harriss JV, Maika SD, Kuziel WA, King HL, Olson EN, et al. (2002). Bop encodes a musclerestricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nat Genet 31, 25-32.
14. Cho HS, Kelly JD, Hayami S, Toyokawa G, Takawa M, Yoshimatsu M, Tsunoda T, Field HI, Neal DE, Ponder BA, et al. (2011). Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia 13, 676-684.
15. Cho HS, Toyokawa G, Daigo Y, Hayami S, Masuda K, Ikawa N, Yamane Y, Maejima K, Tsunoda T, Field HI, et al. (2011). The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G(1) /S transition in cancer cells via transcriptional regulation of the HOXA1 gene. Int J Cancer, E-pub ahead of print.
16. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, et al. (2011). Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 128, 574-586.
17. Hayami S, Yoshimatsu M, Veerakumarasivam A, Unoki M, Iwai Y, Tsunoda T, Field HI, Kelly JD, Neal DE, Yamaue H, et al. (2010). Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer 9, 59.
18. Toyokawa G, Cho HS, Iwai Y, Yoshimatsu M, Takawa M, Hayami S, Maejima K, Shimizu N, Tanaka H, Tsunoda T, et al. (2011). The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prev Res (Phila) 4, 2051-2061.
19. Toyokawa G, Cho HS, Masuda K, Yamane Y, Yoshimatsu M, Hayami S, Takawa M, Iwai Y, Daigo Y, Tsuchiya E, et al. (2011). Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia 13, 887-898.
20. Toyokawa G, Masuda K, Daigo Y, Cho HS, Yoshimatsu M, Takawa M, Hayami S, Maejima K, Chino M, Field HI, et al. (2011). Minichromosome maintenance protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Mol Cancer 10, 65.
21. Olsburgh J, Harnden P, Weeks R, Smith B, Joyce A, Hall G, Poulsom R, Selby P, and Southgate J (2003). Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol 199, 41-49.
22. Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, et al. (2011). Dysregulation of PRMT1 and PRMT6, type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 128, 562-573.
23. Masaki T, Tanabe M, Nakamura K, and Soejima M (1981). Studies on a new proteolytic enzyme from Achromobacter lyticus M497-1. I. Purification and some enzymatic properties. Biochim Biophys Acta 660, 44-50.
24. Masuda A and Dohmae N (2010). Automated protein hydrolysis delivering sample to a solid acid catalyst for amino acid analysis. Anal Chem 82, 8939-8945.
25. Cho HS, Suzuki T, Dohmae N, Hayami S, Unoki M, Yoshimatsu M, Toyokawa G, Takawa M, Chen T, Kurash JK, et al. (2011). Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res 71, 1-6.
26. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, and Dryja TP (1986). A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643-646.
27. Ianari A, Natale T, Calo E, Ferretti E, Alesse E, Screpanti I, Haigis K, Gulino A, and Lees JA (2009). Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 15, 184-194.
28. Trimarchi JM and Lees JA (2002). Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3, 11-20.
29. Knudsen ES and Wang JY (2010). Targeting the RB-pathway in cancer therapy. Clin Cancer Res 16, 1094-1099.
30. Harbour JW, Luo RX, Dei Santi A, Postigo AA, and Dean DC (1999). Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98, 859-869.
31. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, and Weinberg RA (1992). Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70, 993-1006.
32. Carr SM, Munro S, Kessler B, Oppermann U, and La Thangue NB (2011). Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO J 30, 317-327.
33. Saddic LA, West LE, Aslanian A, Yates JR III, Rubin SM, Gozani O, and Sage J (2010). Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem 285, 37733-37740.
34. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, and Nakamura Y (2004). SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6, 731-740.
35. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, and Furukawa Y (2006). Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 97, 113-118.
36. Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, et al. (2011). Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102, 1298-1305.
37. Portela A and Esteller M (2010). Epigenetic modifications and human disease. Nat Biotechnol 28, 1057-1068.
38. Schneider R, Bannister AJ, and Kouzarides T (2002). Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci 27, 396-402.
39. Sparmann A and van Lohuizen M (2006). Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6, 846-856.
40. Black PC, Agarwal PK, and Dinney CP (2007). Targeted therapies in bladder cancer-an update. Urol Oncol 25, 433-438.
41. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, and Vogelzang NJ (2010). Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11, 861-870.
42. Komatsu S, Imoto I, Tsuda H, Kozaki KI, Muramatsu T, Shimada Y, Aiko S, Yoshizumi Y, Ichikawa D, Otsuji E, et al. (2009). Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 30, 1139-1146.
43. Copeland RA, Solomon ME, and Richon VM (2009). Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 8, 724-732.
44. Spannhoff A, Heinke R, Bauer I, Trojer P, Metzger E, Gust R, Schule R, Brosch G, Sippl W, and Jung M (2007). Target-based approach to inhibitors of histone arginine methyltransferases. J Med Chem 50, 2319-2325.